Clinical trial NCT00475566: A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System
Official title: A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atherosclerosis
Peripheral Vascular Disease
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2007-05-21
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal lesions.

Abbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The decision to discontinue the study is not related to any safety concern. The rationale for this proposal is based on the following considerations:

The performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and no stent fractures, and the rate of additional revascularizations has been stable since approximately 14 months after the procedure.

Evaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature show low rates of death, reintervention and stent fracture, which are consistent with STRIDES and demonstrate the safety of the nitinol stent platform of the DYNALINK-E.

Long-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E - everolimus tissue concentration drops below the quantifiable limit by approximately 17 months after implant, and vascular response to the coating is normal with widely patent lumens and struts incorporated into vessel tissue.

The safety and performance of the DYNALINK-E has been substantiated by its clinical and pre-clinical data, and by the clinical data of similar products. Given the demonstrated mechanical integrity of the stent along with the evidence of a healthy long-term vascular response, there is a reasonable expectation of continued low event rates.

Detailed description: A prospective, Non-Randomized, Single-arm, Multi-center, Clinical Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for the Treatment of Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions.

Eligibility criteria: Inclusion Criteria:

* Rutherford Becker Category 2-5
* Single de novo or restenotic lesion in the superficial femoral or proximal popliteal artery
* Disease segment length 30-170 mm
* \>50% diameter stenosis or total occlusion
* Target reference vessel diameter 4.3-7.3 mm

Exclusion Criteria:

* Target lesion previously treated with stent or surgery
* Rutherford Becker Category 0, 1, or 6
* Immunosuppressive disorder or currently receiving immunosuppressive agents
* Serum creatinine \>2.5 mg/dl

Primary outcomes:
measure: In-stent binary restenosis (>50% stenosis), as measured by duplex ultrasound
timeFrame: 6 months
Secondary outcomes:
measure: Angiographic in-stent binary restenosis rate (>50%)
timeFrame: 12 months
measure: Angiographic mean in-stent late loss, in-stent mean minimum lumen diameter (MLD), percent diameter stenosis
timeFrame: 12 months
measure: Primary, and secondary patency
timeFrame: 1, 6, 12, 18 months, 2, 3, 4, 5 years
Other outcomes:
Locations:
city: Klagenfurt
country: Austria
facility: Landeskrankenhaus Klagenfurt
city: Wien
country: Austria
facility: Allgemeines Krankenhaus der Stadt Wien- AKH Wien
city: Dendermonde
country: Belgium
facility: Sint Blasius Hospital
city: Gent
country: Belgium
facility: ZOL St. Jan
city: Gent
country: Belgium
facility: University Hospital
city: Bad Krozingen
country: Germany
facility: Herzzentrum Bad Krozingen
city: Berlin
country: Germany
facility: The Jewish Hospital Berlin
city: Leipzig
country: Germany
facility: Herzzentrum Leipzig
city: Tübingen
country: Germany
facility: University Hospital Tübingen
city: Mercogliano
country: Italy
facility: Casa di Cura di Montevergine
Study officials:
affiliation: Allgemeines Krankenhaus der Stadt Wien
name: Johannes Lammer, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lammer J, Scheinert D, Vermassen F, Koppensteiner R, Hausegger KA, Schroe H, Menon RM, Schwartz LB. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. J Vasc Surg. 2012 Feb;55(2):400-5. doi: 10.1016/j.jvs.2011.08.048. Epub 2011 Nov 1.
citation: Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011 Aug;54(2):394-401. doi: 10.1016/j.jvs.2011.01.047. Epub 2011 Jun 12.